An online article that was recently posted on Medscape discussed some issues that we should be aware of if we are older than 65, especially if we are considering using any of the GLP-1 receptor agonists (Lambrrg, E. (2026, February 3).1

GLP-1 receptor agonists such as semaglutide and tirzepatide have become among the most widely requested medications for weight loss and diabetes management. They can improve blood sugar control, reduce cardiovascular risk, and produce meaningful weight loss. However, in adults over age 65, the risk-benefit balance fundamentally changes.

​Aging brings several baseline vulnerabilities that interact dangerously with GLP-1 medications. Older adults experience reduced muscle mass and strength (sarcopenia), declining bone density, lower thirst response and kidney reserve, increased fall risk, higher rates of polypharmacy (commonly defined as the concurrent use of five or more medications ), and higher prevalence of frailty and malnutrition.
​
GLP-1 medications amplify several of these vulnerabilities because they reduce appetite, slow stomach emptying, promote rapid weight loss, and cause gastrointestinal side effects. The result is that older adults are far more prone to complications from the same effects that younger adults tolerate without difficulty.

Accelerated muscle loss
This is arguably the single most important concern. Weight loss from GLP-1 drugs does not selectively remove fat—it also reduces lean body mass, including muscle. After age 65, muscle loss accelerates naturally, and muscle is critical for balance, mobility, independence, fall prevention, and metabolic health. Rapid weight loss in older adults can push patients from independent to frail to fall-prone with surprising speed.

This progression leads to falls, hospitalization, disability, and loss of independence. Clinicians increasingly emphasize resistance training and high protein intake specifically to counter this risk. Unfortunately, many older patients on GLP-1 medications do not receive this guidance.

Bone loss and fracture risk
Rapid weight loss reduces the mechanical loading that keeps bones strong through reduced stimulation of bone formation, disruption of bone mineral balance, and loss of the muscle forces that protect bone. Evidence shows that older adults with diabetes using GLP-1 medications had approximately 12% higher fracture risk than those using other diabetes drugs, and hip fractures were more common in clinical trials of semaglutide.

This is especially concerning for postmenopausal women, patients with osteopenia or osteoporosis, and anyone with a history of falls. A hip fracture in an older adult is a major life-changing event, typically associated with high morbidity and mortality.

Dehydration and kidney injury
GLP-1 medications commonly cause nausea, vomiting, diarrhea, and reduced thirst and appetite. Older adults already have reduced thirst sensation, reduced kidney reserve, and higher baseline risk of dehydration. Even mild gastrointestinal symptoms can lead to severe dehydration, acute kidney injury, and hospitalization. This is one of the most common serious complications in older patients using GLP-1 drugs.

Malnutrition from appetite suppression
Older adults often tend to have a reduced appetite to begin with, and when using this class of drugs they may over-restrict calories once appetite drops, leading to protein deficiency, vitamin and mineral deficiencies, worsening frailty, immune suppression, and slower healing. Experts now recommend 60 to 90 grams of protein daily, dietitian involvement, and close nutritional monitoring (when using these drugs). This risk is often underestimated, but it can have profound consequences on our functional independence.

Hypoglycemia when GLP-1s are combined with other diabetes drugs
GLP-1 drugs alone rarely cause low blood sugar, but the risk rises significantly when combined with insulin or sulfonylureas. Older adults are especially vulnerable to hypoglycemia, which can cause falls, confusion, cardiac arrhythmias, and hospitalization. Medication regimens often need careful adjustment when GLP-1 therapy begins.

Neurologic symptoms and dizziness
Dizziness is one of the most common neurologic side effects in older users, and it can be caused by dehydration, orthostatic hypotension (a sudden, significant drop in blood pressure upon standing or changing positions), reduced calorie intake, or rapid weight loss. In older adults, dizziness significantly increases fall risk, creating a dangerous cycle where medication side effects directly threaten the independence the patient is trying to preserve.

Experts recommend regular lab monitoring (especially of kidney function), slower dose escalation, nutrition counseling, hydration goals of approximately 64 ounces daily, resistance training several times weekly, and avoiding compounded versions of GLP-1 drugs. Dose escalation should never occur until the current dose is well tolerated.

Absolute contraindications include personal or family history of medullary thyroid cancer, MEN2 syndrome, severe gastroparesis (delayed stomach emptying) or bowel obstruction, and end-stage renal disease or dialysis. Strong relative contraindications include moderate to severe dementia, chronic kidney disease stage 4, baseline frailty or sarcopenia, and severe osteoporosis or frequent falls. These conditions dramatically increase complication risk and may make GLP-1 therapy more harmful than helpful.

GLP-1 medications can be powerful and beneficial, even in older adults, but in this population the biggest risks are not cosmetic or metabolic—they are functional and structural. Muscle loss leads to frailty and falls. Bone loss leads to fractures. Dehydration leads to kidney injury. Malnutrition leads to decline and disability.

For older adults, the key question is not simply "Will this help me lose weight?" It is "Will this help me stay strong, stable, and independent?" When used in carefully selected patients with close monitoring, nutrition support, resistance training, and attention to hydration and protein intake, GLP-1 medications can be helpful. Without that supervision, they can unintentionally accelerate the very problems aging patients most want to avoid — loss of strength, loss of mobility, and loss of independence.

1. Lambrrg, E. (2026, February 3). Older Patients Have Specific Risks for GLP-1 Use. Medscape, Retrieved from, https://www.medscape.com/viewarticle/older-patients-have-specific-risks-glp-1-use-2026a10003bb

Peak brain efficiency occurs in early 30s
The research confirms that brain connectivity and organizational efficiency peak around age 32, after which the brain enters a long stabilization period. This finding aligns with previous research showing plateaus in cognitive function and personality traits during this time.

Major structural shift at age 66
Perhaps most significant is the identification of age 66 as a major turning point where brain connectivity begins meaningful deterioration. This isn't gradual aging — it represents a distinct shift in how the brain organizes itself.​

Non-linear development
The study emphasizes that brain aging isn't a smooth, continuous process but rather proceeds through distinct phases, each with its own characteristics and trajectories. Understanding these phases could help explain why certain conditions emerge at specific life stages.

​Yes, it possibly could. Here's why this brain research may be highly relevant to MC:

The age connection
MC typically develops in people during their 50s through 70s, with peak incidence in the 60s. This timing strikingly overlaps with the fourth era of brain development — the period beginning at age 66 when brain connectivity starts to deteriorate. This correlation is unlikely to be coincidental.

The gut-brain Axis
The gut and brain communicate bidirectionally through multiple pathways:

• The vagus nerve directly connects the gut and brain
• The autonomic nervous system regulates intestinal function
• Neurotransmitters produced in the gut affect brain function and vice versa
• Stress responses originating in the brain directly impact gut inflammation

This research suggests that MC patients, particularly those in or approaching their mid-60s, might benefit from:​

1. Enhanced stress management practices, recognizing that brain changes may affect stress processing
2. Autonomic nervous system training (breathing exercises, HRV biofeedback, vagal tone improvement)
3. Earlier intervention strategies for those with MC risk factors approaching age 66
4. Recognition that the gut-brain connection becomes even more important as brain connectivity changes
5. Consideration of therapies that support both brain and gut health simultaneously

1. Mousley, A., Bethlehem, R.A.I., Fang-Cheng Yeh, F-C., and Astle, D. E. (2025). Topological turning points across the human lifespan. Nature Communications, 16, 10055 Retrieved from https://www.nature.com/articles/s41467-025-65974-8

A recent randomized controlled trial published in Nature Medicine has generated significant interest by demonstrating that a short, monthly dietary intervention (a fasting-mimicking diet) can improve both symptoms and inflammatory markers in patients with Crohn's disease (Kulkarni, et al., (2026).1 The findings are notable because dietary guidance in inflammatory bowel disease (IBD) has historically been limited, and the study suggests that targeted metabolic stress, rather than continuous dietary restriction, may influence immune activity and inflammation.

However, while the results are promising for Crohn's disease, their applicability to microscopic colitis (MC) is far from straightforward, and requires careful consideration.

The clinical trial followed 97 patients with mild-to-moderate Crohn's disease over three months. Participants in the intervention group followed a five-day, calorie-restricted, plant-based diet each month, consuming approximately 700 to 1,100 calories per day, while eating normally for the remainder of the month.

The results were impressive. Approximately 69% of participants achieved clinical response (meaning significant symptom improvement), and about 65% achieved clinical remission. The study also documented significant reductions in fecal calprotectin, a key marker of intestinal inflammation, along with decreases in inflammatory lipid mediators (such as prostaglandins and leukotrienes, for example) and immune signaling activity. Interestingly, many participants reported improvement after just one five-day cycle, suggesting a relatively rapid physiological effect.

Although the study wasn't designed to definitively establish causation, several biological mechanisms were proposed. Markers of systemic inflammation such as C-reactive protein and inflammatory cytokines declined, indicating a broad anti-inflammatory effect. Gene expression changes in immune cells suggested reduced inflammatory signaling, representing immune system modulation. Alterations in fatty-acid-derived signaling molecules may help regulate immune responses. Researchers also hypothesized that gut microbiota changes could contribute, although this remains under investigation.

Crohn's disease has long lacked clear dietary strategies supported by strong clinical evidence. This study is one of the first to demonstrate that a structured, short-duration dietary intervention can produce measurable biological changes and that diet may influence disease activity independently of continuous restriction. This represents a significant shift away from traditional approaches that focus on long-term elimination diets or assume diet plays only a minor supportive role.

This is where caution becomes necessary. Although Crohn's disease and MC are both classified as IBDs, their underlying mechanisms differ significantly in ways that directly affect whether this dietary approach would be helpful, irrelevant, or potentially harmful for MC patients.

Location and type of inflammation:
Crohn's disease involves patchy inflammation that can affect any part of the gastrointestinal tract, penetrating through multiple layers of the intestinal wall. By contrast, MC involves superficial, mucosal inflammation that does not penetrate through multiple layers of the intestinal wall. Most medical professionals mistakenly believe that since MC is diagnosed by examining biopsy samples taken from the mucosa of the colon, the disease does not affect other sections of the digestive tract. However, there's plenty of valid published medical research verifying that the small intestine is commonly inflamed in about half of MC patients. And many MC patients can argue from their own personal experience that the disease can cause aphthous ulcers in the mouth and on their lips, pancreatic inflammation, gallbladder issues, and problems with various other organs in the digestive system.

Immune drivers:
​Crohn's disease involves complex immune dysregulation with multiple pathways activated simultaneously. MC is often strongly linked to immune reactions to specific dietary antigens and medications—a more targeted trigger mechanism.

Symptom triggers:
Crohn's disease symptoms are primarily inflammation-driven, meaning reducing inflammation often reduces symptoms. MC is frequently trigger-driven, with specific foods, drugs, and bile acids directly provoking symptoms regardless of overall inflammatory status.

Plant-based composition may cause problems.
​The fasting-mimicking diet used in the study relied on plant-based meals, which commonly include significant amounts of fiber, legumes, and certain carbohydrates. These are frequent triggers for MC patients and often worsen diarrhea rather than improving it. What calms inflammation in Crohn's disease could directly provoke symptoms in MC through a completely different mechanism.

The diet doesn't address antigen exposure.
MC symptoms are often driven by specific dietary sensitivities such as gluten, casein, or soy. A fasting-mimicking diet reduces overall calories but does not necessarily eliminate the specific offending antigens that trigger MC reactions. For many MC patients, it's not about how much you eat but exactly what you eat. A low-calorie diet that still contains gluten, for example, would provide no benefit and might cause active harm.
​
The diet carries a risk of electrolyte imbalance.
MC patients often experience chronic diarrhea leading to sodium loss, magnesium depletion, and fluid imbalance. A five-day low-calorie diet could exacerbate dehydration and increase risk of cardiac arrhythmias or severe fatigue in susceptible individuals. This is a real safety concern that wasn't relevant in the Crohn's study population but becomes significant for MC patients already dealing with electrolyte vulnerability.

Short term intervention does not mean long-term control.
Even if inflammation markers decreased temporarily during the fasting period, MC typically requires consistent, ongoing avoidance of specific triggers, not intermittent intervention. A monthly five-day diet wouldn't address the daily exposure to problem foods during the other 25 days of the month, which is when MC symptoms would likely return or persist.

Despite these significant limitations, the study does suggest a few concepts that could have relevance for understanding MC, even if the specific intervention doesn't translate directly.

Periodic metabolic reset:
Short-term dietary changes may influence immune signaling pathways in ways we don't fully understand yet. This mechanism might exist in MC as well, though it would need to be tested specifically.
Reduced inflammatory signaling:
If similar immune-modulating mechanisms apply across different IBD types, some MC patients might theoretically experience temporary symptom relief or reduced immune activation from metabolic changes. However, this remains entirely speculative without MC-specific research.
​
Diet can powerfully modulate gut immunity:
​Perhaps most importantly, the study reinforces that diet can affect immune activity in the gut more powerfully than previously recognized — a principle that absolutely applies to MC, even if the specific dietary approach doesn't.

​Rather than adopting the fasting-mimicking diet directly (which could be ineffective or harmful), MC patients should view this study as supporting a broader principle: diet can modulate immune activity in the gut, and nutritional strategies can influence disease activity when properly individualized.

​For MC, this reinforces existing clinical observations. Identifying and eliminating personal triggers remains the critical foundation of dietary management. Nutritional strategies can genuinely influence disease activity, not just symptoms. Immune modulation through diet is scientifically plausible and increasingly well-documented, but it must be individualized based on each patient's specific triggers and tolerance.

The fasting-mimicking diet study represents an important advance in understanding how diet can affect IBD in general. It demonstrates that structured dietary interventions can produce real, measurable changes in immune function and inflammation. However, the results apply specifically to Crohn's disease, not MC. Key elements of the diet (particularly its plant-based composition and calorie restriction approach) may be problematic or entirely ineffective for MC patients. Most critically, the study does not address the trigger-driven nature of MC, which is fundamentally different from the inflammation-driven mechanism in Crohn's disease.

This study highlights an evolving reality in gastroenterology: diet is not merely supportive background therapy but may play a central role in regulating immune function. However, as with most research in IBD, one size does not fit all.

For MC, success still depends on identifying individual triggers through careful elimination and reintroduction trials, maintaining electrolyte balance and adequate hydration, supporting gut barrier integrity over time with appropriate nutrients, and using medications like budesonide when dietary management alone is insufficient (not on short-term, generalized dietary interventions designed for a different disease).

The fasting-mimicking diet research is conceptually interesting and scientifically important for advancing our understanding of diet-immune interactions. But for now, it's not directly actionable for MC patients.

1. Kulkarni, C., Fardeen, T., Gubatan, J., Ye, J., Jarr, K., Dickson, E., . . . Sinha S. R. (2026). A fasting-mimicking diet in patients with mild-to-moderate Crohn’s disease: a randomized controlled trial. Nature Medicine, 32, pp 1023–1033. Retrieved from https://www.nature.com/articles/s41591-025-04173-w#citeas

The review highlights a fundamental issue. Many gastrointestinal disorders, including MC, rely heavily on subjective symptom reporting rather than easily visible objective findings. This creates what researchers call "a perfect environment for dismissal."

Unlike a broken bone visible on X-ray or elevated glucose confirming diabetes, MC requires specific diagnostic criteria, including taking multiple biopsies during colonoscopy, and examining them under a microscope. The colon typically looks normal to the naked eye during the procedure. If the gastroenterologist doesn't take biopsies, or doesn't take enough biopsies from the right locations, the patient will be told that everything is fine despite chronic, watery diarrhea that's destroying the patient's quality of life.

This diagnostic gap, where the patient experiences severe symptoms but standard visualization shows nothing, is precisely where medical gaslighting thrives. When confirmation isn't immediately obvious, clinicians may default to skepticism rather than deeper investigation.

Our own survey, done a couple of years ago, shows that of 1451 MC patients who responded to the survey, only about 59% of them were diagnosed in a year or less. About 24% required from one to 5 years to receive a diagnosis, and about 17% required more than 5 years to receive a diagnosis.

The research identifies several factors within the system that contribute to this problem, all of which apply directly to MC.

Diagnostic uncertainty is mismanaged.
When physicians cannot immediately explain symptoms, they can downplay them, attribute them to stress or anxiety, or avoid deeper investigation, rather than acknowledging uncertainty and continuing to search for answers. For MC patients, this often means being labeled with IBS and sent away with fiber supplements despite ongoing severe diarrhea, even though the conditions are completely different and require different treatments.

The review emphasizes that uncertainty itself isn't the problem. The problem can be found in how that uncertainty is managed. Saying "I'm not sure what's causing this yet, so let's take the next diagnostic step” would be appropriate. Saying "your tests are normal, so it's probably just stress" is gaslighting.

Time constraints are a factor.
Modern clinical practice often allows only 10 to 15 minutes for appointments, with limited time for complex symptom histories. For MC patients whose symptoms may involve food triggers, medication reactions, fluctuating patterns, systemic effects like joint pain or fatigue, and complex bathroom urgency that's difficult to describe briefly, this time constraint makes thorough evaluation nearly impossible.

Multi-system conditions get oversimplified into single complaints, complex symptom patterns are missed entirely, and the rushed physician focuses only on the most obvious presenting symptom rather than the full clinical picture. The complete story, describing the progression of symptoms, the patterns noticed, and the things that make it better or worse, almost never gets heard.

Implicit bias is common.
Certain groups are disproportionately affected by medical dismissal, and the research documents this clearly. Women's symptoms are more likely to be attributed to psychological causes rather than investigated medically. Patients from marginalized racial and ethnic backgrounds have their pain and symptoms taken less seriously. Socioeconomic factors influence how credible physicians find patient reports.

Since MC affects women far more than men (particularly collagenous colitis, which occurs in women at rates 7 to 9 times higher than men), and primarily affects people over 60 who may already face age-based dismissal, MC patients are especially vulnerable to these biases. Consequently, a 65-year-old woman reporting chronic diarrhea is more likely to be told "it's just part of getting older" or "you're anxious about aging" than a 45-year-old man with identical symptoms.

Communication failures are common.
Gaslighting isn't always intentional. It often arises from poor explanation of diagnostic thinking, failure to validate the patient's experience, and overreliance on false reassurance without actual evidence. When a gastroenterologist says "everything looks fine" after a colonoscopy without biopsies, they may genuinely mean the visual inspection was normal. But the patient hears "nothing is wrong with you," which is categorically false if MC is present.

The physician's failure to explain that "the colon looked normal visually, but we need microscopic examination to rule out certain conditions" creates a communication gap that leaves patients feeling dismissed and confused about why they're still suffering.

The research makes a critical distinction that MC patients should understand: not all diagnostic uncertainty or physician disagreement constitutes gaslighting. Medicine involves genuine uncertainty, and sometimes multiple evaluation steps are needed before reaching a diagnosis.

Appropriate care includes:

• Acknowledging when something is uncertain or unclear
• Explaining the diagnostic reasoning process
• Continuing to investigate when symptoms persist despite initial negative findings
• Saying "I don't know yet, but let's figure this out together"
• Referring to specialists when symptoms fall outside the physician's expertise
• Validating that the patient is genuinely experiencing the reported symptoms even when the cause isn't yet clear

Gaslighting occurs when:

• Symptoms are dismissed without adequate evaluation (no biopsies taken during colonoscopy for chronic diarrhea)
• Patients are made to feel unreliable, irrational, or overly anxious
• Symptoms are attributed to psychological causes without ruling out medical causes firstThe physician stops investigating despite persistent, severe symptoms
• Patient reports are treated as less credible than test results, even when the test wasn't designed to detect the condition in question

The effects of medical gaslighting aren't merely emotional—they're clinically significant and well-documented:

Delayed diagnosis: MC patients may go years, literally years, without correct identification of their condition, during which time they suffer preventable complications like malnutrition, electrolyte imbalances, dehydration, bone loss, and severe quality of life impairment.

Worsening disease: Untreated or mismanaged MC can progress, and complications like severe electrolyte depletion can become dangerous. Additionally, being told to increase fiber intake or take standard anti-diarrheal medications without addressing the underlying inflammation can worsen symptoms.

Loss of trust in healthcare: Patients who have been repeatedly dismissed often disengage from the medical system entirely, avoiding care even when they need it, or delaying seeking help until symptoms become emergencies.

Psychological harm: Patients begin to doubt their own perceptions and reality, wondering if they're imagining symptoms or if something is genuinely wrong. This gaslighting-induced self-doubt can be deeply damaging and can persist even after diagnosis is finally obtained.

MC has several characteristics that make patients especially susceptible to diagnostic invalidation:

Invisible to standard examination: The hallmark of MC is that the colon looks completely normal during colonoscopy, and diagnosis absolutely requires microscopic examination of biopsies. If biopsies aren't taken, diagnosis is impossible.

Symptom fluctuation: MC often has periods of relative remission followed by flares, making it easy for physicians to dismiss symptoms as exaggerated if the patient happens to be seen during a calmer period.

Highly individualized triggers: Food and medication triggers vary dramatically between patients, making it hard to fit MC into standardized treatment protocols. Physicians unfamiliar with MC may not understand this variability.

Systemic effects are often unrecognized: Fatigue, joint pain, brain fog, and other extra-intestinal symptoms are common in MC but are rarely mentioned in brief diagnostic criteria, leading physicians to view these as separate, unrelated complaints rather than part of the disease pattern.

Overlap with common diagnoses: Because chronic diarrhea is also a symptom of IBS, and because IBS is far more widely known than MC, many physicians stop at IBS diagnosis without considering MC as a differential.

Older patient population: MC primarily affects people over 50, and age-based bias means symptoms in older adults are more likely to be dismissed as "normal aging" or "just part of getting older."

The review proposes several evidence-based strategies to reduce medical gaslighting, which MC patients can use as a framework for advocating for better care:

Bias-aware communication: Clinicians should recognize their own assumptions, validate patient experiences explicitly, and avoid premature diagnostic closure. For MC patients, this means that physicians should acknowledge that chronic watery diarrhea is not normal, regardless of age or gender of the patient, that symptoms are real and warrant investigation, and that initial negative findings don't close the diagnostic process.

Transparent diagnostic reasoning: Instead of simply dismissing symptoms, providers should explain what has been ruled out with specific tests, what remains uncertain and requires further investigation, and what the logical next diagnostic steps are. For example: "The colonoscopy showed no visible inflammation, which rules out ulcerative colitis and Crohn's disease. However, we haven't yet ruled out MC, which requires biopsies. Let's schedule that next."

Use of standardized diagnostic frameworks: Diagnostic criteria and symptom severity scales provide structure, increase diagnostic confidence, and reduce subjective bias. For MC, this means following established diagnostic algorithms that include biopsy protocols rather than relying solely on clinical impressions.

Multidisciplinary care: Complex conditions often require collaboration across specialties and integration of multiple perspectives. This directly addresses the fragmentation problem in modern medicine where each specialist sees only one piece of the puzzle.

Practical strategies for MC patients facing dismissal: If you're experiencing medical gaslighting in your attempts to diagnose or treat MC, these strategies can help:

Keep a journal: Keep a detailed symptom diary including number of bowel movements per day, stool characteristics, foods eaten, medications taken, and any patterns you notice. Objective data is harder to dismiss than general descriptions.

Research your symptoms: Understand that chronic watery diarrhea warrants colonoscopy with biopsies to rule out MC. Being informed helps you advocate effectively.

Prepare specific questions: Write down exactly what you want to ask and bring the written list. Time pressure makes it easy to forget critical questions during an appointment.
g support: Having another person present can help ensure you're heard and can corroborate your account if the physician seems skeptical.

Be specific and direct: Instead of "I have digestive problems," say "I have 8 to 12 watery bowel movements per day with urgency, and this has continued for six months."

Use the phrase; "This is significantly affecting my quality of life.": Physicians are trained to respond to quality-of-life impact.

Ask directly for biopsies: "I understand the colonoscopy may look normal visually, but I'd like biopsies taken to rule out MC, which is only visible microscopically."

Request explanations: If told "everything is normal," ask "What specific conditions have been ruled out by this test?" and "What conditions haven't been ruled out yet that could cause these symptoms?"

Challenge psychological attributions: If symptoms are attributed to stress or anxiety, respond with: "I'm willing to explore that possibility, but I'd like medical causes ruled out first with appropriate testing."

Ask for documentation: "Can you note in my chart that I requested biopsies and explain why they weren't done?" This creates accountability.

Get a second opinion: Find a gastroenterologist with specific experience in MC, ideally at an academic medical center.

Request your medical records: You have a legal right to your complete records. Review them for accuracy and to see what the physician actually documented about your visit.

File a patient complaint if appropriate: If you were genuinely dismissed without adequate evaluation, filing a formal complaint with the medical practice or hospital creates a record and may prevent future patients from similar experiences.

Consider a patient advocate: Many hospitals have patient advocates who can help navigate the system and ensure you're heard.

Don't give up: Your symptoms are real. Persistence in seeking proper diagnosis is not being difficult — it's appropriate self-advocacy.

Certain situations warrant more urgent action:

• You have severe symptoms (more than 10 bowel movements daily, significant weight loss, severe dehydration, blood in stool) that are being dismissed
• A colonoscopy was performed without biopsies despite your specific request for them
• You've been told multiple times "nothing is wrong" but symptoms continue to severely impair your life
• You're being prescribed medications (like fiber supplements or standard anti-diarrheals) that are making symptoms worse, but your physician won't change course
• You feel unsafe, unheard, or actively disbelieved by your current provider

In these cases, finding a new physician isn't giving up — it's recognizing that the current relationship is not serving our medical needs.

The formal recognition of medical gaslighting in peer-reviewed literature represents an important shift in medicine. It signals that patient experience is being taken more seriously, that communication is being recognized as a clinical tool with measurable impact, and that systemic flaws in healthcare delivery are being acknowledged rather than denied.

But recognition alone isn't enough. Individual patients still must navigate a system that frequently fails them, and knowledge of these systemic problems doesn't immediately change how individual physicians practice or how rushed appointment schedules fail to allow for complex case evaluation.

Underlying this entire discussion is a tension at the heart of modern medicine — the medical system excels at analyzing isolated, clearly defined conditions but struggles profoundly with complex, interconnected conditions that don't fit neatly into a single specialty.

MC can involve immune dysregulation, food sensitivities, medication reactions, gut-brain axis disruption, mast cell involvement, autonomic dysfunction, and systemic inflammation. When a condition spans immune, neurological, gastrointestinal, and endocrine systems simultaneously, patients often fall through the cracks between specialties.

The problem is not simply that MC is difficult to diagnose — it's actually quite straightforward once biopsies are taken. The problem is how the medical system responds when symptoms don't immediately fit familiar patterns. The typical response is dismissal, rather than investigation, with premature diagnostic closure rather than systematic evaluation, with assumptions about the patient's credibility rather than assumptions about the limitations of initial testing.

This research confirms what many MC patients have long known from experience: the problem is not that some conditions are difficult to diagnose — the problem is how the medical system responds to that difficulty.

When diagnostic uncertainty leads to dismissal rather than continued investigation, when normal-appearing colonoscopy results close the diagnostic process despite ongoing severe symptoms, when patient reports are valued less than incomplete test results, patients are left without answers, without treatment, and often without support.

For MC patients, the implications are clear:

Persistent symptoms deserve persistent medical attention. Chronic diarrhea is not normal and is not something you should "just live with."

Lack of visible abnormality does not equal absence of disease. MC is defined by being invisible to the naked eye, and that's why biopsies exist.

Validation is not optional—it's a core component of appropriate medical care. Believing patients when they report symptoms is not being "nice" — it's being competent.

All of us have the right to advocate for thorough evaluation. Requesting biopsies, asking for explanations, seeking second opinions, and insisting on continued investigation when symptoms persist are not being difficult. Those are appropriate ways to advocate for our own healthcare.
Our symptoms are real. Our suffering is real. And we deserve a physician who believes us and is willing to do the diagnostic work necessary to help. If we're not getting that, it's not a failure on our part — it's a failure of the system, and we have every right to seek care elsewhere until we find a provider who takes our symptoms seriously and investigates appropriately.

Medical gaslighting in MC is not rare, it's not just our imagination, and it's increasingly being recognized as a systemic problem that requires systemic solutions. Until those solutions are widely implemented, individual patients must arm themselves with knowledge, documentation, and the confidence to advocate persistently for the care they deserve.

1. Mustafa, N., Nima, J., Klaus, M., and Anthony, S. (2026). Medical Gaslighting in Gastroenterology: A Narrative Review from Pediatric and Adult Practice. Hepatology Advances, Retrieved from https://www.ghadvances.org/article/S2772-5723(26)00082-8/fulltext

If you're caring for someone with both microscopic colitis (MC) and dementia or Alzheimer's disease, you're facing a uniquely challenging situation. While these two conditions are rarely discussed together in medical literature, they frequently occur in the same person, and managing both conditions simultaneously requires specific strategies that most caregivers have to figure out on their own. This guide provides practical, evidence-based approaches to help you prevent complications, reduce your loved one's distress, and maintain their quality of life.

MC typically appears after age 60, making it primarily a disease of older adults. This overlaps directly with the age range when dementia and Alzheimer's disease are most common. Because both conditions increase with age, many caregivers find themselves managing this difficult combination, yet specific guidance remains scarce.

Despite the somewhat confusing way that the healthcare system classifies it, MC is indeed an inflammatory bowel disease, that's usually characterized by chronic watery diarrhea, urgency, fecal incontinence, abdominal discomfort, and nighttime bowel movements. Unlike Crohn's disease or ulcerative colitis, the colon usually looks normal during a colonoscopy, so diagnosis requires microscopic examination of biopsies. This makes the disease difficult to recognize and it's often misdiagnosed as irritable bowel syndrome.

In elderly patients, these symptoms can severely affect daily functioning and independence. The constant urgency and frequent accidents can be physically exhausting and emotionally devastating, even for cognitively normal individuals. When dementia is added to the picture, the challenges multiply.

Dementia fundamentally changes how MC presents, and how it must be managed. Understanding these specific challenges will help caregivers anticipate problems, and allow them to intervene early., when necessary

Loss of symptom awareness:
Patients with dementia may forget to report diarrhea, fail to recognize the sensation of urgency, or not understand the need to reach the bathroom quickly. This dramatically increases the risk of incontinence episodes, which can be distressing for both patient and caregiver.

Inability to follow dietary restrictions:
Diet is often a crucial part of MC management, but people with dementia may forget which foods cause symptoms, refuse unfamiliar foods that are "safe," or snack unpredictably throughout the day. This makes dietary control nearly impossible without constant caregiver supervision.

Dramatically increased dehydration risk:
This is one of the most dangerous aspects of managing both conditions together. Chronic diarrhea causes significant fluid loss, and dementia patients often forget to drink fluids, lose their perception of thirst, or actively resist drinking. This combination can rapidly lead to electrolyte imbalance, weakness, falls, and worsening confusion. Dehydration also makes cognitive symptoms worse, creating a vicious cycle.

Communication breakdown:
Your loved one may be unable to explain symptoms like abdominal pain, urgency, fatigue, or dizziness. You may have to rely entirely on behavioral clues rather than verbal comments, making it easy to miss important symptoms until they become severe.

Recognizing MC symptoms through behavior changes:
Because dementia patients often cannot verbally communicate their symptoms, you need to watch for behavioral signs that may indicate MC is active or worsening:

• Sudden agitation or restlessness without apparent cause
• Pacing or repeated attempts to stand up
• Clutching or holding the abdomen
• Increased confusion beyond their baseline
• Unexplained fatigue or wanting to lie down more than usual
• Resisting sitting down (may indicate abdominal cramping)

In dementia patients, physical discomfort almost always appears as behavioral changes. Learning to read these signals is essential.

Dehydration:
This is the most immediate and dangerous complication. Chronic diarrhea increases fluid loss significantly, and symptoms of dehydration include weakness, increased confusion, dizziness, and decreased urine output. In dementia patients, even mild dehydration can quickly worsen cognitive symptoms, increase fall risk, and lead to hospitalization.

What to watch for:
Dark urine, decreased frequency of urination, dry mouth, sunken eyes, confusion worse than baseline, weakness, or skin that doesn't bounce back quickly when pinched.

Malnutrition:
Frequent diarrhea reduces nutrient absorption and often suppresses appetite. Warning signs include progressive weight loss, muscle weakness, fatigue, and loose-fitting clothes. Malnutrition accelerates cognitive decline and increases vulnerability to infections.

Skin breakdown:
Frequent incontinence dramatically increases the risk of skin irritation, pressure ulcers, and infection. This is particularly problematic in patients with limited mobility. Prompt hygiene after each bowel movement, and consistent use of barrier creams, are essential for prevention of skin problems.

Clinical guidelines recommend budesonide as the first-line therapy for active MC. This locally acting corticosteroid can significantly reduce diarrhea and improve quality of life with minimal systemic side effects.

Other medications sometimes used include bismuth subsalicylate (Pepto-Bismol), loperamide (Imodium) for symptom control, bile acid sequestrants if bile acid diarrhea is contributing, and immunosuppressive medications in severe cases.

These treatments can dramatically improve symptoms, but caregivers must monitor medication side effects carefully in dementia patients. Work closely with your loved one's physician to find the most effective regimen, with the fewest cognitive side effects.

Maintain a consistent, simple diet.
​Many MC patients improve significantly with elimination of trigger foods, most commonly gluten, dairy, soy, high-fiber foods, spicy foods, and certain high-fat foods. Consistency is crucial because frequent dietary changes can actually worsen symptoms.

Practical tips:
​

• Keep a simple rotation of 5-7 safe meals
• Prepare foods the same way each time
• Avoid introducing new foods during flares
• Label safe foods clearly if other family members are helping with care
• Consider working with a dietitian who understands both MC and dementia care

Encourage frequent, small amounts of fluids:Small, frequent drinks throughout the day are much more effective than trying to get your loved one to drink large amounts at once. Offer fluids every hour when awake.

Good options:

• Electrolyte solutions (Pedialyte, for example)
• Diluted fruit juices
• Broths or clear soups
• Herbal teas (caffeine-free)
• Water with a slice of fruit for flavor

Strategies that help:

• Use cups with measurements so you can track intake
• Offer favorite beverages
• Serve fluids at preferred temperatures
• Use straws if easier for your loved one
• Include hydrating foods like asparagus, cauliflower, almond milk, soup, or gelatin   

A predictable toileting schedule can dramatically reduce incontinence episodes and the stress associated with urgency.

Effective routines:
​

• Take your loved one to the bathroom immediately after each meal (this takes advantage of the gastrocolic reflex)
• Schedule bathroom visits every 2-3 hours throughout the day
• Ensure easy, quick access to bathrooms or keep a bedside commode nearby
• Use nightlights to make nighttime bathroom trips safer
• Dress your loved one in clothing that's easy to remove quickly
• Keep wipes, barrier cream, and clean clothes readily accessible   

Certain medications commonly prescribed to older adults can trigger or significantly worsen MC. These include NSAIDs (ibuprofen, naproxen), proton pump inhibitors (omeprazole, pantoprazole), and certain antidepressants (SSRIs). Review the complete medication list with your loved one's physician regularly and ask if any medications might be contributing to diarrhea.

Keep a simple log that tracks:
​

• Number of bowel movements per day
• ​Fluid intake
• Foods eaten
• Behavioral changes
• Accidents or incontinence episodes

This information is invaluable for medical appointments and helps you identify patterns or triggers.

One practical bathroom addition that can greatly ease the burden of managing frequent diarrhea and incontinence is a bidet or bidet toilet attachment. For patients experiencing multiple bowel movements daily, repeated wiping with toilet paper quickly leads to skin irritation, soreness, rashes, and breakdown of fragile skin. Warm water cleansing is much gentler, provides more thorough cleaning with far less effort, and helps prevent dermatitis, fungal infections, and pressure sores. For caregivers, bidets significantly reduce the time and physical effort required for cleaning after each bowel movement and often eliminate the need for frequent showers.

Many modern bidet seats include features like automatic water spray, adjustable temperature, warm air drying, and remote controls. Once familiar with the device, some dementia patients can use it with minimal assistance, helping maintain dignity and independence longer. Simple bidet toilet attachments that install under an existing toilet seat are inexpensive, require no electrical connection, and are often sufficient for caregiving situations. More advanced bidet seats provide additional comfort features but cost more.

Be sure that the water pressure is adjusted to a gentle level, and keep soft towels nearby for drying, and continue using barrier creams if any skin irritation occurs. While bidets remain underused in the United States, for caregivers managing both microscopic colitis and dementia, they can be one of the simplest and most effective tools for improving hygiene, reducing skin complications, and enhancing quality of life for both patient and caregiver.

Incontinence is often the most distressing aspect of MC for both patient and caregiver. Approach this with compassion and practical preparation.

Supplies that help:

• Absorbent underwear or pads appropriate for the level of incontinence
• Waterproof mattress covers
• Disposable bed pads for chairs and beds
• Barrier creams to protect skin
• No-rinse cleansing foams or wipes
• Clean clothing kept in multiple locations for quick changes

Maintaining dignity:
​

• Respond calmly to accidents without showing frustration
• Use matter-of-fact language: "Let's get you cleaned up"
• Ensure privacy during cleaning and changing
• Never scold or express disgust
• Remember that your loved one likely feels embarrassed and distressed   

​Recent research has revealed extensive communication between the gut and brain through immune, neural, and microbial pathways. Studies suggest that changes in intestinal structure and the gut microbiome may influence brain disorders, including Alzheimer's disease. This "gut-brain axis" means that intestinal inflammation might potentially affect neurological health.

While the exact relationship between MC and dementia progression remains unclear, the evidence suggests that controlling intestinal inflammation may have benefits beyond symptom relief. Managing MC well may help stabilize cognitive symptoms and overall well-being.

Managing both conditions is physically and emotionally demanding. You cannot provide good care if you're exhausted and overwhelmed.

Resources that can help:

• Home health services for assistance with personal care
• Continence care supplies covered by insurance or Medicare
• Dietitian guidance for meal planning
• Caregiver support groups (in-person or online)
• Care assistance to give you regular breaks
• Adult day programs that can provide supervision and social interactio

Don't hesitate to ask for help. Caring for someone with both MC and dementia is genuinely a two-person job during active disease.

Contact your loved one's physician promptly if you notice:

• Signs of severe dehydration (very dark urine, no urination for 8+ hours, extreme weakness)
• Sudden worsening of diarrhea beyond their usual pattern
• Unintentional weight loss
• Blood in stool
• Persistent, severe abdominal pain
• New or dramatically worsening confusion
• Sudden weakness or inability to walk
• Signs of skin infection around the rectal area

​These may indicate complications requiring urgent treatment. Don't wait, because early intervention prevents hospitalizations.

With proper treatment, most MC patients can achieve remission or at least significant symptom control. Budesonide and dietary modifications can be remarkably effective. While dementia complicates management, it doesn't make good MC control impossible — it just requires more vigilance and creative problem-solving from caregivers.

Your role is absolutely essential. Physicians can prescribe medications, but you are the one who ensures hydration, manages diet, prevents skin breakdown, recognizes behavioral changes, and maintains your loved one's dignity and comfort. How well you can perform your role as caregiver's ultimately determines your loved ones long-term health and well-being.

Although MC and dementia are rarely discussed together in the medical literature, their overlap in older adults makes combined management increasingly common and important. You're navigating a challenging path with limited guidance, and that makes your role as caregiver unusually difficult.

But you're not alone, and with awareness of the specific challenges, consistent daily routines, proper medical treatment, vigilant monitoring for complications, and support for yourself as a caregiver, you can make sure that your loved one has the best opportunities for maintaining comfort and quality of life, despite the challenging conditions. Focus on what you can control, ask for help when you need it, and remember that even small improvements in symptoms can significantly enhance your loved one's daily experience and your caregiving chores.